Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva

Area of Science:

• Genetics and Molecular Biology
• Rare Diseases Research
• Drug Discovery and Development

Background:

• Fibrodysplasia Ossificans Progressiva (FOP) is a rare autosomal-dominant disorder causing progressive heterotopic ossification.
• Over 95% of FOP cases stem from a specific mutation (R206H) in the ACVR1/ALK2 receptor, leading to aberrant activation.
• Reducing the activity of the hyperactive ACVR1 receptor presents a promising therapeutic avenue for FOP.

Purpose of the Study:

• To develop a method for reducing ACVR1 expression in FOP patient cells.
• To investigate the efficacy of exon skipping using phosphorodiamidate morpholino oligomers (PMOs) for ACVR1 knockdown.
• To establish a screening platform for antisense oligomers targeting dominant genetic diseases.

Main Methods:

• Utilized phosphorodiamidate morpholino oligomers (PMOs) to induce exon skipping in ACVR1 messenger RNAs (mRNAs).
• Applied the developed method to FOP patient-derived cells.
• Demonstrated the reduction of ACVR1 expression through this exon skipping strategy.

Main Results:

• Successfully reduced ACVR1 expression in FOP patient cells via PMO-mediated exon skipping.
• Validated the potential of this approach for targeting the mutated ACVR1 receptor.
• Established a versatile strategy applicable for screening therapeutic antisense oligomers.

Conclusions:

• PMO-mediated exon skipping is a viable strategy to decrease ACVR1 expression in FOP.
• This approach holds promise for developing targeted therapies for Fibrodysplasia Ossificans Progressiva.
• The methodology can be extended to screen for treatments for other autosomal-dominant genetic diseases.